Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 220

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Effects of Sibutramine Treatment in Obese Adolescents: A Randomized Trial

Berkowitz, Robert I., Fujioka, Ken, Daniels, Stephen R., Hoppin, Alison G., Owen, Stanford, Perry, Arlette C., Sothern, Melinda S., Renz, Cheryl L., Pirner, Mark A., Walch, Julia K., Jasinsky, Olga, Hewkin, Ann C., Blakesley, Vicky A., for the Sibutramine Adolescent Study Group* · 2006 · Annals of Internal Medicine

Abstract

BACKGROUND: Increased prevalence of adolescent obesity requires effective treatment options beyond behavior therapy. OBJECTIVE: To see whether sibutramine reduced weight more than placebo in obese adolescents who were receiving a behavior therapy program. DESIGN: 12-month, 3:1 randomized, double-blind trial conducted from July 2000 to February 2002. SETTING: 33 U.S. outpatient clinics. PARTICIPANTS: 498 participants 12 to 16 years of age with a body mass index (BMI) that was at least 2 units more than the U.S. weighted mean of the 95th percentile based on age and sex, to the upper limit of 44 kg/m2. INTERVENTIONS: Site-specific behavior therapy plus 10 mg of sibutramine or placebo. Blinded study medication dose was uptitrated to 15 mg or placebo at month 6 if initial BMI was not reduced by 10%. MEASUREMENTS: Body mass index, waist circumference, body weight, fasting lipid and glycemic variables, safety, and tolerability. RESULTS: Seventy-six percent of patients in the sibutramine group and 62% of patients in the placebo group completed the study. The estimated mean treatment group difference at month 12 (linear mixed-effects model) favored sibutramine for change from baseline in BMI (-2.9 kg/m2 [95% CI, -3.5 to -2.2 kg/m2]) and body weight (-8.4 kg [CI, -9.7 to -7.2 kg]) (P < 0.001 for both). The sibutramine group had greater improvements in triglyceride levels, high-density lipoprotein cholesterol levels, insulin levels, and insulin sensitivity (P < or = 0.001 for all). The rate of tachycardia was greater with sibutramine vs. placebo (12.5% vs. 6.2%; difference, 6.3 percentage points [CI, 1.0 to 11.7 percentage points]) but did not lead to increased withdrawal (2.4% vs. 1.5%; difference, 0.9 percentage point [CI, -1.7 to 3.5 percentage points]). LIMITATIONS: The 1-year study duration precluded assessment of long-term weight maintenance and putative health benefits and harms, and 24% and 38% of the sibutramine and placebo groups, respectively, did not complete follow-up. CONCLUSIONS: Sibutramine added to a behavior therapy program reduced BMI and body weight more than placebo and improved the profile of several metabolic risk factors in obese adolescents.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-145-2-200607180-00005

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 220

Metadata

Authors
Berkowitz, R. I., Fujioka, K., Daniels, S. R., Hoppin, A. G., Owen, S., Perry, A. C., Sothern, M. S., Renz, C. L., Pirner, M. A., Walch, J. K., Jasinsky, O., Hewkin, A. C., Blakesley, V. A., & for the Sibutramine Adolescent Study Group*
Venue
Annals of Internal Medicine
Published
2006-07-18
Volume
145
Issue
2
Pages
81-90
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2125226484
Cited by
220
References
9
FWCI
22.83
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Sibutramine Treatment in Obese Adolescents: A Randomized Trial. https://app.cochat.ai/papers/10.7326/0003-4819-145-2-200607180-00005
The paper
Berkowitz, R. I., Fujioka, K., Daniels, S. R., Hoppin, A. G., Owen, S., Perry, A. C., Sothern, M. S., Renz, C. L., Pirner, M. A., Walch, J. K., Jasinsky, O., Hewkin, A. C., Blakesley, V. A., & for the Sibutramine Adolescent Study Group*. (2006). Effects of Sibutramine Treatment in Obese Adolescents: A Randomized Trial. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-145-2-200607180-00005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.